Kids

Positive expiratory pressure oscillating device can preserve lung function in children

November 18, 2022

1 minute read

Source/explanations

Source:

Bakker E, et al. Abstract 272. Presented at: North American Cystic Fibrosis Conference; November 3-5, 2022; Philadelphia.

disclosures:
Healio was unable to confirm the researchers’ relevant financial disclosures at the time of reporting.


We could not process your request. Try again later. If you continue to experience this issue, please contact customerservice@slackinc.com.

Use of a positive expiratory pressure oscillating device alone or with additional airway clearance improved lung function in children with cystic fibrosis, according to data presented at the North American Cystic Fibrosis Conference.

“Airway clearance therapy is a cornerstone of cystic fibrosis care,” Elizabeth H. Baker, PhD, associate professor in the department of sociology at the University of Alabama at Birmingham, and a colleague wrote. “Multiple airway clearance therapy modalities are available, but there is little evidence to support the use of one over the other.”


After adjusting for all covariates, the researchers found that users of OPEP had a 6.6 higher percentage of predicted FEV over a 5-year period1 (P = .03) than non-users. Source: Adobe Stock

In a retrospective longitudinal analysis, Baker and colleagues assessed 146 patients with cystic fibrosis (CF) aged 7 to 20 years from one cystic fibrosis center to observe changes in lung function over 5 years when using an oscillating positive expiratory device. pressure (OPEP) (Aerobika, Monaghan), according to the study abstract.

Researchers stratified patients based on OPEP use, and they controlled for several sociodemographic and clinical covariates, including race, gender, parental education, smoke exposure, and CF genotype.

Researchers reported lung function as percent predicted FEV1 and measured this, as well as age, at each clinical encounter.

Of the total cohort, 58 (39.7%) patients used OPEP as their main form of airway clearance therapy or in combination with a high-frequency chest wall oscillation vest.

Researchers noted that these patients were more likely to have the F508del homozygous CF genotype and less likely to have exposure to smoke and Pseudomonas aeruginosa.

After adjusting for all covariates, the researchers found that users of OPEP had a 6.6 higher percentage of predicted FEV over a 5-year period1 (P = .03) than non-users. Furthermore, OPEP users with parents who did not have a college education had a 12.7 higher percentage of predicted FEV1 (93.5% vs. 80.8%; P = .004), which the researchers wrote, indicates that the device may be especially helpful for children of lower socioeconomic status.

In addition, researchers reported that both OPEP users and non-users had a 1.5% annual decline in lung function (P < .001).

“The clinical efficacy of the device should be evaluated in a randomized controlled trial,” Baker and colleagues wrote. “Future research should also determine the most appropriate age to introduce the device. Because the use of OPEP seems to be especially beneficial for the most vulnerable individuals, it should be explored as a way to reduce differences in lung function.”

Leave a Comment